Davis B R, Cutler J A, Gordon D J, Furberg C D, Wright J T, Cushman W C, Grimm R H, LaRosa J, Whelton P K, Perry H M, Alderman M H, Ford C E, Oparil S, Francis C, Proschan M, Pressel S, Black H R, Hawkins C M
University of Texas School of Public Health, Houston, USA.
Am J Hypertens. 1996 Apr;9(4 Pt 1):342-60. doi: 10.1016/0895-7061(96)00037-4.
Are newer types of antihypertensive agents, which are currently more costly to purchase on average, as good or better than diuretics in reducing coronary heart disease incidence and progression? Will lowering LDL cholesterol in moderately hypercholesterolemic older individuals reduce the incidence of cardiovascular disease and total mortality? These important medical practice and public health questions are to be addressed by the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind trial in 40,000 high-risk hypertensive patients. ALLHAT is designed to determine whether the combined incidence of fatal coronary heart disease (CHD) and nonfatal myocardial infarction differs between persons randomized to diuretic (chlorthalidone) treatment and each of three alternative treatments--a calcium antagonist (amlodipine), an angiotensin converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin). ALLHAT also contains a randomized, open-label, lipid-lowering trial designed to determine whether lowering LDL cholesterol in 20,000 moderately hypercholesterolemic patients (a subset of the 40,000) with a 3-hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor, pravastatin, will reduce all-cause mortality compared to a control group receiving "usual care." ALLHAT's main eligibility criteria are: 1) age 55 or older; 2) systolic or diastolic hypertension; and 3) one or more additional risk factors for heart attack (eg, evidence of atherosclerotic disease or type II diabetes). For the lipid-lowering trial, participants must have an LDL cholesterol of 120 to 189 mg/dL (100 to 129 mg/dL for those with known CHD) and a triglyceride level below 350 mg/dL. The mean duration of treatment and follow-up is planned to be 6 years. Further features of the rationale, design, objectives, treatment program, and study organization of ALLHAT are described in this article.
目前平均购买成本更高的新型抗高血压药物,在降低冠心病发病率和病情进展方面是否与利尿剂一样好或优于利尿剂?在中度高胆固醇血症的老年个体中降低低密度脂蛋白胆固醇(LDL胆固醇)是否会降低心血管疾病的发病率和总死亡率?这些重要的医学实践和公共卫生问题将由抗高血压和降脂治疗预防心脏病发作试验(ALLHAT)来解答,这是一项针对40000名高危高血压患者的随机双盲试验。ALLHAT旨在确定随机接受利尿剂(氯噻酮)治疗的人与三种替代治疗——钙拮抗剂(氨氯地平)、血管紧张素转换酶抑制剂(赖诺普利)和α-肾上腺素能阻滞剂(多沙唑嗪)——中的每一种相比,致命性冠心病(CHD)和非致命性心肌梗死的合并发病率是否存在差异。ALLHAT还包含一项随机、开放标签的降脂试验,旨在确定在20000名中度高胆固醇血症患者(40000名患者中的一个子集)中使用3-羟基-3-甲基戊二酰辅酶A(HMG CoA)还原酶抑制剂普伐他汀降低LDL胆固醇,与接受“常规治疗”的对照组相比,是否会降低全因死亡率。ALLHAT的主要入选标准为:1)年龄55岁或以上;2)收缩压或舒张压高血压;3)一项或多项额外的心脏病发作风险因素(例如,动脉粥样硬化疾病或II型糖尿病的证据)。对于降脂试验,参与者的LDL胆固醇必须为120至189mg/dL(已知患有CHD的患者为100至129mg/dL),甘油三酯水平低于350mg/dL。治疗和随访的平均持续时间计划为6年。本文将描述ALLHAT的基本原理、设计、目标、治疗方案和研究组织的进一步特点。